Coherus Shelves Eylea Biosimilar And Rules Out Early-Stage Biosimilar Development

Biosimilars Leader Coherus Marks New Era With Immuno-Oncology Play

 
• By Dean Rudge
Wooden Blocks Chance Change
Coherus is "still quite open to biosimilar deals" but will will consider them carefully • Source: Shutterstock

More from Strategy

More from Business